Lupin has launched Tavaborole Topical Solution, 5% having received an approval from the United States Food and Drug Administration (USFDA). The product will be manufactured at Lupin’s facility in Pithampur, India.
Tavaborole Topical Solution, 5%, is generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Tavaborole Topical Solution (RLD: Kerydin), 5% has an estimated annual sales of $53 million in the U.S.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
